课题基金 / 基金详情

MSC 2013: Adult Stem Cell Therapy and Regenerative Medicine

MSC 2013: Adult Stem Cell Therapy and Regenerative Medicine
MSC 2013:成体干细胞治疗和再生医学
批准号:
8597780
负责人:
STANTON L. GERSON
金额:
$2.5万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-02 至 2014-07-31

项目摘要

项目成果

STANTON L. GERSON的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):MSC 2013由国家再生医学中心(NCRM),克利夫兰临床和转化科学联盟(CTSC),凯斯西储大学医学院(CWRUSOM),克利夫兰诊所(CC)和大学医院案例医学中心(UHCMC)提出。MSC 2013将于2013年8月19日至21日在俄亥俄州克利夫兰市中心的克利夫兰万豪酒店举行。MSC 2013会议总监包括Arnold Caplan博士;罗伯特·迪恩斯博士; Stanton Gerson,医学博士; Jan Nolta,Ph.D.; Frank巴里,博士;马亨德拉·拉奥,工商管理硕士,博士学位;和迈克尔·吉尔基,工商管理硕士M.S.选择会议主任是因为他们在成人干细胞研究方面的活跃,世界知名的地位以及地理多样性。许多规划会议和电子邮件讨论已经发生,并形成了该计划,以服务于他们领导的领域。 构想说明 MSC 2013将有平台和海报会议,强调来自各种人类和动物组织的成人源性干细胞的临床前和临床应用。MSC 2013将为转化再生医学的研究、思想和前沿突破提供一个交流和讨论的论坛。 目标受众 在再生医学中使用干细胞的创新者 目标受众是多方面的:成人干细胞治疗领域新的和有经验的研究人员,学生(研究生和博士后),医生和对这些细胞类型的治疗机会感兴趣的商业实体。初级研究人员和学生将获得一个场地,在海报会议和邀请演讲中介绍和讨论他们的研究。 会议目标 MSC 2013将 * 提供一个论坛,用于交流和讨论转化再生医学的研究,想法和前沿突破。 * 专注于从各种人类和动物组织中分离,鉴定,纯化,可塑性和成人来源的干细胞的临床应用。 * 强调组织工程和再生医学的最新技术和这些细胞制剂的临床应用。 * 特色邀请思想领袖的讲座,并提供平台会议,海报会议,以及初级研究人员和学生展示和讨论他们的研究的场所。 * 提供产品开发的监管方法-FDA、商业风险、终点和患者人群。 * 将生物技术细胞治疗行业与研究人员和临床研究中心联系起来,包括临床试验状态报告。 提案具体目标 这项R13提案的具体目标是为研究生、博士后和临床研究员参加MSC 2013提供旅行和注册支持,重点是支持妇女和少数民族人口的参与。一个重要的考虑因素是学生和研究员的多样化和参与,因此将为处境不利和代表性不足的学生参加会议分配资金。目标是改善再生医学领域的职业发展,包括扩大他们在干细胞技术方面的知识,并与受资助的主要研究人员进行互动。所有申请人都会 要求提交一份海报进行展示,被选中的人将在MSC 2013上展示他们的工作。我们计划为大约20名研究生和博士后研究员提供旅行奖励,通过口头和海报介绍、网络活动和共同主持会议,参加并"积极"参与海安会2013年会议。他们还将被要求帮助编写会议记录与我们的会议主任一致。
英文摘要
DESCRIPTION (provided by applicant): MSC 2013 is being presented by: The National Center for Regenerative Medicine (NCRM), the Cleveland Clinical and Translational Science Consortium (CTSC), Case Western Reserve University School of Medicine (CWRUSOM), Cleveland Clinic (CC), and University Hospitals Case Medical Center (UHCMC). MSC 2013 will take place in Cleveland, OH, August 19-21, 2013 at the Cleveland Marriott Downtown at Key Center. MSC 2013 Conference Directors include Arnold Caplan, Ph.D.; Robert Deans, Ph.D.; Stanton Gerson, M.D.; Jan Nolta, Ph.D.; Frank Barry, Ph.D.; Mahendra Rao, M.B.B.S., Ph.D.; and Michael Gilkey, M.B.A., M.S. The Conference Directors were chosen due to their active, world-renowned statures in adult stem cell research as well as geographic diversity. Numerous planning meetings and email discussions have already occurred and have shaped the program to serve the field they lead. Vision Statement MSC 2013 will have platform and poster sessions emphasizing preclinical and clinical applications of adult- derived stem cells from a variety of human and animal tissues. MSC 2013 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. Target Audience Innovators in the use of stem cells in regenerative medicine The target audience is multi-fold: new and experienced investigators in the adult stem cell therapy field, students (graduate and post-doctoral), physicians, and commercial entities interested in therapeutic opportunities with these cell types. Junior investigators and students will be given a venue to present and discuss their research in poster sessions and invited presentations. Conference Objectives MSC 2013 will * Offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. * Focus on the isolation, characterization, purity, plasticity and clinical uses of adult-derived stem cells from a variety of human and animal tissues. * Emphasize state-of-the-art technologies and clinical utility of these cell preparations for tissue engineering and regenerative medicine. * Feature invited lectures from thought-leaders and provide platform sessions, poster sessions, and a venue for junior investigators and students to present and discuss their research. * Provide a regulatory approach to product development - FDA, commercial risks, endpoints, and patient populations. * Link biotechnology cell therapy industry to investigators and clinical sites including clinical trial status reports. Proposal Specific Aim The specific aim of this R13 proposal is to provide travel and registration support for graduate students, postdoctoral students and clinical fellows to attend MSC 2013, with an emphasis on supporting the participation of women and minority populations. An important consideration is the diversification and participation of students and fellows, so funds will be allocated for disadvantaged and under-represented students to attend the meeting. The goal is to improve career development in the field of regenerative medicine, including broadening their knowledge in stem cell technology and interacting with funded principal investigators. All applicants will be required to submit a poster for presentation and those chosen will present their work at MSC 2013. We plan to provide travel awards for approximately 20 graduate students and post- doctoral fellows to attend and "actively" participate in MSC 2013 through oral and poster presentations, networking events and co-chairing of sessions. They will also be asked to help write the conference proceedings in concert with our Conference Directors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
  • 批准号:
    10084628
  • 项目类别:
  • 资助金额:
    $30.81万
  • 财政年份:
    2020
  • 负责人:
    STANTON L. GERSON
  • 依托单位:
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
  • 批准号:
    10267199
  • 项目类别:
  • 资助金额:
    $31.24万
  • 财政年份:
    2020
  • 负责人:
    STANTON L. GERSON
  • 依托单位:
Molecular determinants of lung cancer in HIV infected and uninfected individuals in Uganda and Tanzania
  • 批准号:
    10478912
  • 项目类别:
  • 资助金额:
    $31.24万
  • 财政年份:
    2020
  • 负责人:
    STANTON L. GERSON
  • 依托单位:
Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization and imaging
  • 批准号:
    10267194
  • 项目类别:
  • 资助金额:
    $99.09万
  • 财政年份:
    2020
  • 负责人:
    STANTON L. GERSON
  • 依托单位:
海外基金